DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
93
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017

NEW YORK, July 10, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Akari Therapeutics Plc (“Akari” or the “Company”) (NASDAQ: AKTX ) and certain of its officers, on behalf of shareholders who purchased Akari securities between March 30, 2017 and May 11, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aktx .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and specifically that: (1) Dr. Gur Roshwalb (“Roshwalb”), Akari’s Chief Executive Officer (“CEO”), and possibly others, caused false information about Akari to be published, including but not limited to, false information regarding the Phase 2 PNH trial of Coversin; (2) Akari lacked sufficient controls and protections to prevent such behavior; and (3) consequently, Akari’s financial statements were materially false and misleading at all relevant times.

According to the complaint, following an announcement made on May 11, 2017 that Akari’s CEO, Roshwalb, was placed on administrative leave while the Board of Directors investigates the involvement of Akari personnel related to a report issued on April 26, 2017, Akari stock dropped significantly.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/aktx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Akari you have until July 11, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Brixton Metals Expands Thorn Project with New Mineral Claims

Updated Category News Views 198

Brixton Metals Expands Thorn Project with New Mineral Claims Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) has expanded its footprint at the Thorn Project, securing a 100% interest in mineral claims covering 6,446 hectares. These claims, which were previously outside Brixton’s control, sit northwest of the well-known Golden Bear Mine and add ground the company...

Continue Reading
Nutex Health Awaits Q2 Results Amid Regulatory Hurdles

Updated Category News Views 20

Diving headfirst into the grumbles of this healthcare whirlwind we call Nutex Health. They've set the table to drop their Q2 financials on August 6, right after the bell, followed by a chat with investors the next morning. We're talking bumper-to-bumper business news here, and everyone with a slice in NASDAQ: NUTX better have their ears pricked. Nutex Health: A Mixed Bag...

Continue Reading
Arvore Partners LP Announces Impressive October Distribution

Updated Category News Views 183

Arvore Partners LP Declares Monthly Distribution for October Arvore Partners LP is thrilled to share details about the declaration of its monthly distribution for October. This distribution amounts to $687,365, which translates to an impressive 9.06% annualized yield for its unitholders, marking a 7% increase from the previous month. This consistent growth highlights...

Continue Reading
Key Insights on Marathon Petroleum's Upcoming Earnings Call

Updated Category News Views 101

An Overview of Marathon Petroleum's Earnings Expectations Marathon Petroleum (NYSE: MPC) is gearing up for its quarterly earnings announcement. Investors should prepare for necessary insights leading up to the release of this important announcement. Analysts predict a solid earnings per share (EPS) of $3.23 for the upcoming quarter. While it’s crucial for the company to...

Continue Reading
Revolutionizing Male Infertility Research with PacBio's Revio

Updated Category News Views 80

Transforming Male Infertility Research with PacBio's Revio MENLO PARK, Calif. — PacBio (NASDAQ: PACB), a leading name in sequencing solutions, is launching an exciting collaboration with the University Hospital of Münster. This partnership is set to leverage long-read whole genome sequencing to significantly advance research in male infertility and rare diseases....

Continue Reading